Lixte Biotechnology Holdings, Inc. Price & Performance (LIXTW)

Lixte Biotechnology Holdings has secured a Nasdaq extension until July 3, 2025, to meet minimum equity requirements after previously falling short. The company, which recently amended a key clinical trial agreement to reduce costs, must restore at least $2.5 million in equity or risk delisting. Shares remain under pressure following a 66% annual decline.12

Lixte Biotechnology Holdings’ stock has been downgraded to a sell candidate as technical indicators point to further short-term weakness. Despite a recent 0.5% gain, the stock is expected to fall 13.7% over the next three months. Increased trading volume and volatility highlight ongoing risk for investors.32

Lixte Biotechnology Holdings reported a net loss of $3.31 million with no revenue in the latest period, underscoring persistent financial challenges. The company’s negative earnings per share and lack of profitability raise concerns about its ability to meet listing standards and sustain operations without new funding sources.2